A reactivity pattern for discrimination of ER agonism and antagonism based on 3-D molecular attributes.
Various models have been developed to predict the relative binding affinity (RBA) of chemicals to estrogen receptors (ER). These models can be used to prioritize chemicals for further tiered biological testing to assess the potential for endocrine disruption. One shortcoming of models predicting RBA has been the inability to distinguish potential receptor antagonism from agonism, and hence in vivo response. It has been suggested that steroid receptor antagonists are less compact than agonists; thus, ER binding of antagonists may prohibit proper alignment of receptor protein helices preventing subsequent transactivation. The current study tests the theory of chemical bulk as a defining parameter of antagonism by employing a 3-D structural approach for development of reactivity patterns for ER antagonists and agonists. Using a dataset of 23 potent ER ligands (16 agonists, 7 antagonists), molecular parameters previously found to be associated with ER binding affinity, namely global (E(HOMO)) and local (donor delocalizabilities and charges) electron donating ability of electronegative sites and steric distances between those sites, were found insufficient to discriminate ER antagonists from agonists. However, parameters related to molecular bulk, including solvent accessible surface and negatively charged Van der Waal's surface, provided reactivity patterns that were 100% successful in discriminating antagonists from agonists in the limited data set tested. The model also shows potential to discriminate pure antagonists from partial agonist/antagonist structures. Using this exploratory model it is possible to predict additional chemicals for their ability to bind but inactivate the ER, providing a further tool for hypothesis testing to elucidate chemical structural characteristics associated with estrogenicity and anti-estrogenicity.
Schmieder
P
P
US-EPA, NHEERL, Mid-Continent Ecology Division, Duluth, MN 55804, USA. schmieder.patricia@epa.gov
Koleva
Y
Y
Mekenyan
O
O
D000818:Animals; D004703:Endocrine System / Q000187:drug effects; D020847:Estrogen Receptor Modulators / Q000494:pharmacology*; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology*; D005544:Forecasting; D006801:Humans; D008962:Models, Theoretical; D015394:Molecular Structure; D011960:Receptors, Estrogen / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry*; D012997:Solvents; D013329:Structure-Activity Relationship
D020847:Estrogen Receptor Modulators; D004968:Estrogens, Non-Steroidal; D011960:Receptors, Estrogen; D012997:Solvents